The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | IRAKLIA: safety & feasibility of subcutaneous administration of isatuximab using an on-body injector
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the potential of subcutaneous (SC) administration of isatuximab using an on-body injector (OBI) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Cerchione presents the results of the Phase III IRAKLIA trial (NCT05405166), comparing isatuximab SC with intravenous (IV) administration, plus pomalidomide and dexamethasone. Dr Cerchione emphasizes the potential role of isatuximab in the myeloma treatment landscape and notes that personalizing treatment extends beyond target-driven approaches to also include optimizing drug administration. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are in Milan for EHA 2025 where we have seen incredible outstanding novelties in multiple myeloma. I think one of the most important ones is the trial IRAKLIA in which it is shown the non-inferiority of subcutaneous administration isatuximab versus the intravenous one in combination with pomalidomide and dexamethasone. It is injected through a homebody delivery system that is a small button put on the abdomen of the patient through which the drug is administered...
We are in Milan for EHA 2025 where we have seen incredible outstanding novelties in multiple myeloma. I think one of the most important ones is the trial IRAKLIA in which it is shown the non-inferiority of subcutaneous administration isatuximab versus the intravenous one in combination with pomalidomide and dexamethasone. It is injected through a homebody delivery system that is a small button put on the abdomen of the patient through which the drug is administered. This is safe, this avoids an infusion reaction and in some way this is something that can be explored also in other regimens, isatuximab-based. I think the important result from this trial published on JCO some days ago is not only the effectiveness but the quality of life of our patients, the safety, and particularly the satisfaction also of the personnel that is going to manage our patients. I think that in this way we can optimize the use of the drug, we can optimize the spaces in our outpatient’s room and particularly we can optimize the time of our patients and of their caregivers.
I think that this is a basis to be explored and to make the use of isatuximab wider if we consider that we have seen outstanding results also in front-line setting, transplant eligible with the GMMG, transplant ineligible with IMROZ and we know that Isa-KD and Isa-Pom-Dex are some combinations that we are going to continue to use in our daily practice. I think that the home body delivery system, as soon as it will be approved, can optimize our practice and can make isatuximab finally one of the best backbones that we can have in our daily practice.
So I think that personalizing the treatment doesn’t mean today only a target driven approach, but it’s also to personalize the administrations of the drug. I think that IRAKLIA can show that we can improve more and more the feasibility, the maintaining of those dense dose intensity, thanks to the change of formulation and of administration of the drug. So I think that this is an important novelty, such as the improving in terms of efficacy with other clinical trials. Thank you for your attention.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
